Ivosidenib 在新诊断 IDH1 突变急性髓系白血病中诱导深度持久缓解
该研究为 Ivosidenib 一期试验,纳入 34 例不适合标准治疗的新诊断 IDH1 突变 AML 患者,每日口服 500 mg。CR+CRh 率为 42.4%,CR 率 30.3%,中位总生存 12.6 个月,耐受性良好,部分输血依赖患者脱离输血。
要点
- Ivosidenib 单药在不适合标准治疗的新诊断 IDH1 突变 AML 中耐受性良好。
- CR+CRh 率 42.4%,CR 率 30.3%,缓解持久且部分患者实现 IDH1 突变清除。
- 基线输血依赖患者中 42.9% 转为输血独立。
核心结论
- Ivosidenib 单药在新诊断 IDH1 突变 AML 患者中耐受良好,可诱导持久缓解和输血独立。
研究设计与样本
- 一期研究纳入 258 例 IDH1 突变血液系统恶性肿瘤患者,本报告分析其中 34 例不适合标准治疗的新诊断 AML 患者,每日口服 Ivosidenib 500 mg。
- 患者中位年龄 76.5 岁,26 例(76%)为继发性 AML,16 例(47%)曾因前驱血液病接受过至少一种低甲基化药物。
主要发现
- 最常见全等级不良事件为腹泻(18 例,53%)、疲乏(16 例,47%)、恶心(13 例,38%)和食欲下降(12 例,35%)。
- 分化综合征报告于 6 例(18%),其中 3 级及以上 3 例(9%),未导致治疗终止。
- CR+CRh 率为 42.4%(95%CI 25.5%–60.8%),CR 率为 30.3%(95%CI 15.6%–48.7%)。
- CR+CRh 和 CR 的中位持续时间未达到,95%CI 下限分别为 4.6 和 4.2 个月;1 年时分别有 61.5% 和 77.8% 的患者仍处于缓解。
- 中位随访 23.5 个月(范围 0.6–40.9 个月),中位总生存为 12.6 个月(95%CI 4.5–25.7)。
临床怎么用
- 对于不适合标准治疗的新诊断 IDH1 突变 AML 患者,可考虑 Ivosidenib 单药治疗。
- 治疗期间需监测分化综合征,本研究中其发生率为 18%,3 级及以上为 9%。
- 需关注腹泻、疲乏、恶心和食欲下降等常见不良事件。
局限性
- 本研究为一期试验的亚组分析,样本量较小(34 例)。
- 患者为不适合标准治疗的新诊断 AML,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ivosidenib (AG-120) is an oral, targeted agent that suppresses production of the oncometabolite 2-hydroxyglutarate via inhibition of the mutant isocitrate dehydrogenase 1 (IDH1; mIDH1) enzyme. From a phase 1 study of 258 patients with IDH1-mutant hematologic malignancies, we report results for 34 patients with newly diagnosed acute myeloid leukemia (AML) ineligible for standard therapy who received 500 mg ivosidenib daily. Median age was 76.5 years, 26 patients (76%) had secondary AML, and 16 (47%) had received ≥1 hypomethylating agent for an antecedent hematologic disorder. The most common all-grade adverse events were diarrhea (n = 18; 53%), fatigue (n = 16; 47%), nausea (n = 13; 38%), and decreased appetite (n = 12; 35%). Differentiation syndrome was reported in 6 patients (18%) (grade ≥3 in 3 [9%]) and did not require treatment discontinuation. Complete remission (CR) plus CR with partial hematologic recovery (CRh) rate was 42.4% (95% confidence interval [CI], 25.5% to 60.8%); CR 30.3% (95% CI, 15.6% to 48.7%). Median durations of CR+CRh and CR were not reached, with 95% CI lower bounds of 4.6 and 4.2 months, respectively; 61.5% and 77.8% of patients remained in remission at 1 year. With median follow-up of 23.5 months (range, 0.6-40.9 months), median overall survival was 12.6 months (95% CI, 4.5-25.7). Of 21 transfusion-dependent patients (63.6%) at baseline, 9 (42.9%) became transfusion independent. IDH1 mutation clearance was seen in 9/14 patients achieving CR+CRh (5/10 CR; 4/4 CRh). Ivosidenib monotherapy was well-tolerated and induced durable remissions and transfusion independence in patients with newly diagnosed AML. This trial was registered at www.clinicaltrials.gov as #NCT02074839.
引用
- Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020. PMID: 31841594. doi:10.1182/blood.2019002140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。